Courage Therapeutics Inc. and University of Michigan have synthesized peptides acting as melanocortin MC4 receptor (MC4R) agonists and/or MC3 receptor (MC3R) antagonist/partial agonists reported to be ...
MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today announced the dosing of the first patient in a Phase 1a/1b clinical trial of its IL-2 partial ...
Two Sealed Airtight Medical Vials Against Bright Background Front View. Real-world data conflict with a recent meta-analysis including patients from highly selected clinical trial populations.
Use of a gonadotropin-releasing hormone antagonist is associated with lower risks for death than GnRH agonists, a systematic review and meta-analysis found. Use of degarelix, a gonadotropin-releasing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results